NCT00803673已完成1 期
A Single Centre, Randomized, Double-blind, Dose Ascending, Placebo-controlled Study, in Two Parts, to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Inhaled Doses of GSK573719 and Placebo Formulated With the Excipient Magnesium Stearate, in Healthy Subjects and in a Healthy Population of Cytochrome P450 Isoenzyme 2D6 Poor Metabolisers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- General safety and tolerability endpoints: Adverse Events (AE), HR, BP, 12- lead ECG and lung function (FEV1) and clinical laboratory safety tests
研究概览
简要总结
This study is to look at a new formulation of GSK573719 to see if it is safe and tolerated in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female 18 to 65 years of age inclusive.
- •Non-childbearing women or women of child bearing potential who agree to use contraception
- •Subject has had their CYP2D6 genotype confirmed and can be included in either of the following parts:
- •Part 1: may include extensive, intermediate and ultra-rapid metabolizers
- •Part 2: includes only poor (no enzyme activity) metabolizers, with previously confirmed phenotype
- •Body Mass Index within the range 18 - 30 kg/m2 (inclusive).
- •Capable of giving written informed consent
- •Normal ECG;
- •Normal lung function.
- •Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = (cigarettes per day smoked/20) x number of years smoked))
- •A signed and dated written informed consent is obtained from the subject
- •The subject is capable of giving informed consent
- •Available to complete the study
排除标准
- •Any clinically important abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or ECG (12-lead). 24hr Holter monitoring outside normal limits.
- •A history of breathing problems (i.e. history of asthmatic symptomatology).
- •Abnormal ECG.
- •Abnormal blood pressure.
- •Abnormal heart rate
- •The subject has a positive pre-study drug/alcohol screen.
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within three months of screening.
- •A positive test for HIV antibody (if determined by the local SOPs).
- •History of high alcohol consumption within three months of the study
- •The subject has participated in a clinical trial and has received an IP within the following time period prior to the first dosing day in the current study: 30 days, five half-lives or twice the duration of the biological effect of the IP (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs, (except for simple analgesics e.g. paracetamol), including vitamins, herbal and dietary supplements (including St John's Wort) within seven days (or 14 days if the drug is a potential enzyme inducer) or five half-lives (whichever is longer) prior to the first dose of study medication
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56 day period.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine-containing products prior to screening.
- •The subject is unable to use the novel dry powder inhaler correctly.
- •The subject has a known allergy or hypersensitivity to milk protein or the excipients magnesium stearate and lactose monohydrate.
研究组 & 干预措施
Active
Experimental
100mcg 719
干预措施: 100mcg (Drug)
Active 2
Experimental
500mcg '719
干预措施: 500mcg (Drug)
Active 3
Experimental
1000mcg '719
干预措施: 1000mcg (Drug)
Placebo
Placebo Comparator
Placebo '719
干预措施: Placebo (Drug)
结局指标
主要结局
General safety and tolerability endpoints: Adverse Events (AE), HR, BP, 12- lead ECG and lung function (FEV1) and clinical laboratory safety tests
时间窗: Various
次要结局
- Blood and urine levels of study drug(various)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT00950807GlaxoSmithKline176
已完成
1 期
Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy SubjectsPulmonary Disease, Chronic ObstructiveNCT01128634GlaxoSmithKline32
终止
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy SubjectsBronchiectasisNCT02058407GlaxoSmithKline33
已完成
1 期
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy VolunteersType 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00501930GlaxoSmithKline12
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke CigarettesAsthmaNCT03045887GlaxoSmithKline38